| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Wednesday’s Close |
|---|---|---|---|---|---|
| MRK | Merck & Company, Inc. | $70.42 | $187.28B | N/A |
Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO
http://www.zacks.com/stock/news/424416/bristol-myers-bmy-presents-multiple-data-on-opdivo-at-asco?cid=CS-ZC-FT-424416
Jun 04, 2019 - Bristol-Myers (BMY) announces data from multiple studies on immuno-oncology drug, Opdivo, at ASCO.
0
3 Drug Stocks That Could Win From Key FDA Approvals in June
https://www.fool.com/investing/2019/06/04/3-drug-stocks-that-could-win-from-key-fda-approval.aspx?source=iedfolrf0000001
Jun 04, 2019 - Two hope to pick up additional indications for existing blockbuster drugs, while another could score a big victory for a new drug.
0
Company News For Jun 4, 2019
http://www.zacks.com/stock/news/424463/company-news-for-jun-4-2019?cid=CS-ZC--424463
Jun 04, 2019 - Companies In The News Are:
EE,CY,AMGN,MRK
0
Why Cancer-Fighting Stocks & ETFs Are Soaring
http://www.zacks.com/stock/news/424108/why-cancer-fighting-stocks-etfs-are-soaring?cid=CS-ZC-FT-424108
Jun 03, 2019 - The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.
0
Novartis (NVS) Announces Various Data Presentations at ASCO
http://www.zacks.com/stock/news/424089/novartis-nvs-announces-various-data-presentations-at-asco?cid=CS-ZC-FT-424089
Jun 03, 2019 - Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.
0
AstraZeneca's Imfinzi Shows Long-Term Benefits in Lung Cancer
http://www.zacks.com/stock/news/423951/astrazenecas-imfinzi-shows-long-term-benefits-in-lung-cancer?cid=CS-ZC-FT-423951
Jun 03, 2019 - AstraZeneca (AZN) presents follow-up data on Imfinzi from late-stage PACIFIC study evaluating it in lung cancer patients.
0
Roche Presents Positive Data on Xolair & Updates From ASCO
http://www.zacks.com/stock/news/423876/roche-presents-positive-data-on-xolair-updates-from-asco?cid=CS-ZC-FT-423876
Jun 03, 2019 - Roche (RHHBY) reports positive data from late-stage studies on allergic asthma drug, Xolair, for a new indication, and additional results on Tecentriq and Avastin combo at ASCO.
0
Merck's Keytruda Improves 5-Year Survival in Lung Cancer
http://www.zacks.com/stock/news/423872/mercks-keytruda-improves-5-year-survival-in-lung-cancer?cid=CS-ZC-FT-423872
Jun 03, 2019 - Merck (MRK) presents longest follow-up data for Keytruda in advance lung cancer at ASCO 2019. The five-year overall survival rates in the Keytruda arm are better than historical rates
0
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs
http://www.zacks.com/stock/news/422851/roche-rhhby-up-63-ytd-on-strong-demand-for-new-drugs?cid=CS-ZC-FT-422851
May 31, 2019 - Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
0
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
http://www.zacks.com/stock/news/420060/incyte-incy-receives-fda-nod-for-label-expansion-of-jakafi?cid=CS-ZC-FT-420060
May 27, 2019 - Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.
0